Small-molecule inhibitors for autoimmune arthritis: Success, failure and the future

European Journal of Pharmacology

Volumn 747, Issue , 2015, Pages 200-205

  Ho, Ling Jun ^a   Lai, Jenn Haung ^b,c  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Autoimmune arthritis; Janus kinases; P38; Phosphodiesterase 4; Small molecule inhibitors; Spleen tyrosine kinase

Indexed keywords

ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; BRUTON TYROSINE KINASE; BRUTON TYROSINE KINASE INHIBITOR; CELECOXIB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETORICOXIB; JANUS KINASE; MELOXICAM; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; SMALL MOLECULE INHIBITOR; TOFACITINIB; UNCLASSIFIED DRUG; ENZYME INHIBITOR; MOLECULAR LIBRARY;

ARTHRITIS; ARTICLE; AUTOIMMUNE ARTHRITIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; HUMAN; NONHUMAN; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; ANIMAL; ARTHRITIS, RHEUMATOID; ENZYMOLOGY; MOLECULAR LIBRARY; PHARMACOLOGY; THERAPEUTIC USE;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ENZYME INHIBITORS; HUMANS; SMALL MOLECULE LIBRARIES;

EID: 84921465148     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.08.031     Document Type: Article

References (72)

1. Al-Riyami, L., Pineda, M.A., Rzepecka, J., Huggan, J.K., Khalaf, A.I., Suckling, C.J., Scott, F.J., Rodgers, D.T., Harnett, M.M., Harnett, W., 2013. Designing antiinflammatory drugs from parasitic worms: a synthetic small molecule analogue of the Acanthocheilonema viteae product ES-62 prevents development of collagen-induced arthritis. J. Med. Chem. 56, 9982-10002.
2. Allen, M., Svensson, L., Roach, M., Hambor, J., McNeish, J., Gabel, C.A., 2000. Deficiency of the stress kinase p38alpha results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells. J. Exp. Med. 191, 859-870.
3. Beardmore, V.A., Hinton, H.J., Eftychi, C., Apostolaki, M., Armaka, M., Darragh, J., McIlrath, J., Carr, J.M., Armit, L.J., Clacher, C., Malone, L., Kollias, G., Arthur, J.S., 2005. Generation and characterization of p38beta (MAPK11) gene-targeted mice. Mol. Cell. Biol. 25, 10454-10464.
4. Bezbradica, J.S., Medzhitov, R., 2009. Integration of cytokine and heterologous receptor signaling pathways. Nat. Immunol. 10, 333-339.
5. Bohm, C., Hayer, S., Kilian, A., Zaiss, M.M., Finger, S., Hess, A., Engelke, K., Kollias, G., Kronke, G., Zwerina, J., Schett, G., David, J.P., 2009. The alpha-isoform of p38 MAPK specifically regulates arthritic bone loss. J. Immunol. 183, 5938-5947.
6. Buhler, S., Laufer, S.A., 2014. p38 MAPK inhibitors: a patent review (2012-2013). Expert Opin. Ther. Pat. 24, 535-554.
7. Burmester, G.R., Blanco, R., Charles-Schoeman, C., Wollenhaupt, J., Zerbini, C., Benda, B., Gruben, D., Wallenstein, G., Krishnaswami, S., Zwillich, S.H., Koncz, T., Soma, K., Bradley, J., Mebus, C., Investigators, O.S., 2013. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381, 451-460.
8. Cha, H.S., Boyle, D.L., Inoue, T., Schoot, R., Tak, P.P., Pine, P., Firestein, G.S., 2006. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J. Pharmacol. Exp. Ther. 317, 571-578.
9. Chakravarty, S.D., Poulikakos, P.I., Ivashkiv, L.B., Salmon, J.E., Kalliolias, G.D., 2013. Kinase inhibitors: a new tool for the treatment of rheumatoid arthritis. Clin. Immunol. 148, 66-78.
10. Changelian, P.S., Moshinsky, D., Kuhn, C.F., Flanagan, M.E., Munchhof, M.J., Harris, T. M., Whipple, D.A., Doty, J.L., Sun, J., Kent, C.R., Magnuson, K.S., Perregaux, D.G., Sawyer, P.S., Kudlacz, E.M., 2008. The specificity of JAK3 kinase inhibitors. Blood 111, 2155-2157.
11. Choy, E.H., Kavanaugh, A.F., Jones, S.A., 2013. The problem of choice: current biologic agents and future prospects in RA. Nat. Rev. Rheumatol. 9, 154-163.
12. Conti, M., Beavo, J., 2007. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem. 76, 481-511.
13. Cooles, F.A., Isaacs, J.D., 2011. Pathophysiology of rheumatoid arthritis. Curr. Opin. Rheumatol. 23, 233-240.
14. Criado, G., Risco, A., Alsina-Beauchamp, D., Perez-Lorenzo, M.J., Escos, A., Cuenda, A., 2014. Alternative p38 mitogen-activated protein kinases are essential for collagen-induced arthritis. Arthr. Rheumatol. h 10.1002/art.38327i (Article first published online: 28 APR 2014).
15. Damjanov, N., Kauffman, R.S., Spencer-Green, G.T., 2009. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheumatol. 60, 1232-1241.
16. Di Paolo, J.A., Huang, T., Balazs, M., Barbosa, J., Barck, K.H., Bravo, B.J., Carano, R.A., Darrow, J., Davies, D.R., DeForge, L.E., Diehl, L., Ferrando, R., Gallion, S.L., Giannetti, A.M., Gribling, P., Hurez, V., Hymowitz, S.G., Jones, R., Kropf, J.E., Lee, W.P., Maciejewski, P.M., Mitchell, S.A., Rong, H., Staker, B.L., Whitney, J.A., Yeh, S., Young, W.B., Yu, C., Zhang, J., Reif, K., Currie, K.S., 2011. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat. Chem. Biol. 7, 41-50.
17. Dixon, W.G., Hyrich, K.L., Watson, K.D., Lunt, M., Galloway, J., Ustianowski, A., Symmons, D.P., 2010. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann. Rheum. Dis. 69, 522-528.
18. Eriksson, J.K., Karlsson, J.A., Bratt, J., Petersson, I.F., vanVollenhoven, R.F., Ernestam, S., Geborek, P., Neovius, M., 2014. Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial. Ann. Rheum. Dis. h10.1136/annrheumdis-2013-205060i (Published online first 15 April 2014).
19. Fan, H.C., Fernandez-Hernando, C., Lai, J.H., 2014. Protein kinase C isoforms in atherosclerosis: pro- or anti-inflammatory? Biochem. Pharmacol. 88, 139-149.
20. Fleischmann, R., 2013. Back to the future: oral small molecule kinases. Rheumatology 52, 1153-1154.
21. Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C.A., Bradley, J.D., Gruben, D., Wallenstein, G.V., Zwillich, S.H., Kanik, K.S., Investigators, O.S., 2012. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 367, 495-507.
22. Francis, S.H., Blount, M.A., Corbin, J.D., 2011. Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol. Rev. 91, 651-690.
23. Ghoreschi, K., Laurence, A., O'Shea, J.J., 2009. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat. Immunol. 10, 356-360.
24. Goldstein, D.M., Kuglstatter, A., Lou, Y., Soth, M.J., 2010. Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J. Med. Chem. 53, 2345-2353.
25. Hammaker, D., Firestein, G.S., 2010. "Go upstream, young man": lessons learned from the p38 saga. Ann. Rheum. Dis 69 (Suppl 1), i77-i82.
26. Ho, L.J., Lai, J.H., 2004. Chinese herbs as immunomodulators and potential disease-modifying antirheumatic drugs in autoimmune disorders. Curr. Drug Metab. 5, 181-192.
27. Hope, H.R., Anderson, G.D., Burnette, B.L., Compton, R.P., Devraj, R.V., Hirsch, J.L., Keith, R.H., Li, X., Mbalaviele, G., Messing, D.M., Saabye, M.J., Schindler, J.F., Selness, S.R., Stillwell, L.I., Webb, E.G., Zhang, J., Monahan, J.B., 2009. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation. J. Pharmacol. Exp. Ther. 331, 882-895.
28. Inoue, T., Boyle, D.L., Corr, M., Hammaker, D., Davis, R.J., Flavell, R.A., Firestein, G.S., 2006. Mitogen-activated protein kinase kinase 3 is a pivotal pathway regulating p38 activation in inflammatory arthritis. Proc. Natl. Acad. Sci. USA 103, 5484-5489.
29. Jabara, H.H., McDonald, D.R., Janssen, E., Massaad, M.J., Ramesh, N., Borzutzky, A., Rauter, I., Benson, H., Schneider, L., Baxi, S., Recher, M., Notarangelo, L.D., Wakim, R., Dbaibo, G., Dasouki, M., Al-Herz, W., Barlan, I., Baris, S., Kutukculer, N., Ochs, H.D., Plebani, A., Kanariou, M., Lefranc, G., Reisli, I., Fitzgerald, K.A., Golenbock, D., Manis, J., Keles, S., Ceja, R., Chatila, T.A., Geha, R.S., 2012. DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation. Nat. Immunol. 13, 612-620.
30. Jimenez, J.L., Punzon, C., Navarro, J., Munoz-Fernandez, M.A., Fresno, M., 2001. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. J. Pharmacol. Exp. Ther. 299, 753-759.
31. Kalkan, A., Hallert, E., Bernfort, L., Husberg, M., Carlsson, P., 2014. Costs of rheumatoid arthritis during the period 1990-2010: a register-based cost-of-illness study in Sweden. Rheumatology 53, 153-160.
32. Kang, Y.J., Chen, J., Otsuka, M., Mols, J., Ren, S., Wang, Y., Han, J., 2008. Macrophage deletion of p38alpha partially impairs lipopolysaccharide-induced cellular activation. J. Immunol. 180, 5075-5082.
33. Kavanaugh, A., Mease, P.J., Gomez-Reino, J.J., Adebajo, A.O., Wollenhaupt, J., Gladman, D.D., Lespessailles, E., Hall, S., Hochfeld, M., Hu, C., Hough, D., Stevens, R. M., Schett, G., 2014. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann. Rheum. Dis. 73, 1020-1026.
34. Kim, C., Sano, Y., Todorova, K., Carlson, B.A., Arpa, L., Celada, A., Lawrence, T., Otsu, K., Brissette, J.L., Arthur, J.S., Park, J.M., 2008. The kinase p38 alpha serves cell type-specific in flammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression. Nat. Immunol. 9, 1019-1027.
35. Kis, B., Snipes, J.A., Busija, D.W., 2005. Acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fictions, and uncertainties. J. Pharmacol. Exp. Ther. 315, 1-7.
36. Korb, A., Tohidast-Akrad, M., Cetin, E., Axmann, R., Smolen, J., Schett, G., 2006. Differential tissue expression and activation of p38 MAPK alpha, beta, gamma, and delta isoforms in rheumatoid arthritis. Arthritis Rheumatol. 54, 2745-2756.
37. Kumar, N., Goldminz, A.M., Kim, N., Gottlieb, A.B., 2013. Phosphodiesterase 4-targeted treatments for autoimmune diseases. BMC Med. 11, 96.
38. Laurencin, C.T., Khan, Y., 2012. Regenerative engineering. Sci. Transl. Med. 4160ed169.
39. Lee, J.C., Laydon, J.T., McDonnell, P.C., Gallagher, T.F., Kumar, S., Green, D., McNulty, D., Blumenthal, M.J., Heys, J.R., Landvatter, S.W., et al., 1994. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739-746.
40. Lee, J.C., Young, P.R., 1996. Role of CSB/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. J. Leukoc. Biol. 59, 152-157.
41. Lee, Y., Rodriguez, C., Dionne, R.A., 2005. The role of COX-2 in acute pain and the use of selective COX-2 inhibitors for acute pain relief. Curr. Pharm. Des. 11, 1737-1755.
42. Liou, J.T., Huang, H.S., Chiang, M.L., Lin, C.S., Yang, S.P., Ho, L.J., Lai, J.H., 2014. A salicylate-based small molecule HS-Cm exhibits immunomodulatory effects and inhibits dipeptidyl peptidase-IV activity in human T cells. Eur. J. Pharmacol. 726C, 124-132.
43. Lomenick, B., Olsen, R.W., Huang, J., 2011. Identification of direct protein targets of small molecules. ACS Chem. Biol. 6, 34-46.
44. Ma, L., Gong, H., Zhu, H., Ji, Q., Su, P., Liu, P., Cao, S., Yao, J., Jiang, L., Han, M., Ma, X., Xiong, D., Luo, H.R., Wang, F., Zhou, J., Xu, Y., 2014. A novel small-molecule tumor necrosis factor alpha inhibitor attenuates inflammation in a hepatitis mouse model. J. Biol. Chem. 289, 12457-12466.
45. Mocsai, A., Ruland, J., Tybulewicz, V.L., 2010. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat. Rev. Immunol. 10, 387-402.
46. Modena, V., Bianchi, G., Roccatello, D., 2013. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target? Autoimmun. Rev. 12, 835-838.
47. Musumeci, D., Roviello, G.N., Montesarchio, D., 2014. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. Pharmacol. Ther. 141, 347-357.
48. Nijjar, J.S., Tindell, A., McInnes, I.B., Siebert, S., 2013. Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis. Rheumatology 52, 1556-1562.
49. O'Dell, J.R., 2013. Treatment of rheumatoid arthritis. 9th ed. In: Firestein, G.S., Budd, R.C., Gabriel, S.E., McInnes, I.B., O'Dell, J.R. (Eds.), Kelley's Textbook of Rheumatology, 2013. Elsevier, Philadelphia, pp. 1137-1160.
50. O'Dell, J.R., Mikuls, T.R., Taylor, T.H., Ahluwalia, V., Brophy, M., Warren, S.R., Lew, R. A., Cannella, A.C., Kunkel, G., Phibbs, C.S., Anis, A.H., Leatherman, S., Keystone, E., Investigators, C.R., 2013. Therapies for active rheumatoid arthritis after methotrexate failure. N. Engl. J. Med. 369, 307-318.
51. O'Shea, J.J., Holland, S.M., Staudt, L.M., 2013a. JAKs and STATs in immunity, immunodeficiency, and cancer. N. Engl. J. Med. 368, 161-170.
52. O'Shea, J.J., Laurence, A., McInnes, I.B., 2013b. Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat. Rev. Rheumatol. 9, 173-182.
53. Okimoto, N., Futatsugi, N., Fuji, H., Suenaga, A., Morimoto, G., Yanai, R., Ohno, Y., Narumi, T., Taiji, M., 2009. High-performance drug discovery: computational screening by combining docking and molecular dynamics simulations. PLoS Comput. Biol. 5, e1000528.
54. Ollivier, V., Parry, G.C., Cobb, R.R., de Prost, D., Mackman, N., 1996. Elevated cyclic AMP inhibits NF-kappaB-mediated transcription in human monocytic cells and endothelial cells. J. Biol. Chem. 271, 20828-20835.
55. Ono, K., Han, J., 2000. The p38 signal transduction pathway: activation and function. Cell. Signal. 12, 1-13.
56. Pine, P.R., Chang, B., Schoettler, N., Banquerigo, M.L., Wang, S., Lau, A., Zhao, F., Grossbard, E.B., Payan, D.G., Brahn, E., 2007. Infl ammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin. Immunol. 124, 244-257.
57. Poole, R.M., Ballantyne, A.D., 2014. Apremilast: first global approval. Drugs 74, 825-837.
58. Rasheed, Z., Akhtar, N., Haqqi, T.M., 2010. Pomegranate extract inhibits the interleukin-1beta-induced activation of MKK-3, p38alpha-MAPK and transcription factor RUNX-2 in human osteoarthritis chondrocytes. Arthritis Res. Ther. 12, R195.
59. Sabio, G., Arthur, J.S., Kuma, Y., Peggie, M., Carr, J., Murray-Tait, V., Centeno, F., Goedert, M., Morrice, N.A., Cuenda, A., 2005. p38gamma regulates the localisation of SAP97 in the cytoskeleton by modulating its interaction with GKAP. EMBO J. 24, 1134-1145.
60. Schafer, P., 2012. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem. Pharmacol. 83, 1583-1590.
61. Smolen, J.S., Landewe, R., Breedveld, F.C., Buch, M., Burmester, G., Dougados, M., Emery, P., Gaujoux-Viala, C., Gossec, L., Nam, J., Ramiro, S., Winthrop, K., de Wit, M., Aletaha, D., Betteridge, N., Bijlsma, J.W., Boers, M., Buttgereit, F., Combe, B., Cutolo, M., Damjanov, N., Hazes, J.M., Kouloumas, M., Kvien, T.K., Mariette, X., Pavelka, K., van Riel, P.L., Rubbert-Roth, A., Scholte-Voshaar, M., Scott, D.L., Sokka-Isler, T.,Wong, J.B., van der Heijde, D., 2014. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 73, 492-509.
62. Tamura, N., 2012. [Recent findings on phosphoinositide-3 kinase in rheumatic diseases]. Nihon Rinsho Men'eki Gakkai kaishi=Jpn. J. Clin. Immunol. 35, 8-13.
63. Tan, S.L., Liao, C., Lucas, M.C., Stevenson, C., DeMartino, J.A., 2013. Targeting the SYKBTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives. Pharmacol. Ther. 138, 294-309.
64. Terajima, M., Inoue, T., Magari, K., Yamazaki, H., Higashi, Y., Mizuhara, H., 2013. Anti-inflammatory effect and selectivity profile of AS1940477, a novel and potent p38 mitogen-activated protein kinase inhibitor. Eur. J. Pharmacol. 698, 455-462.
65. Troutman, T.D., Hu,W., Fulenchek, S., Yamazaki, T., Kurosaki, T., Bazan, J.F., Pasare, C., 2012. Role for B-cell adapter for PI3K (BCAP) as a signaling adapter linking Tolllike receptors (TLRs) to serine/threonine kinases PI3K/Akt. Proc. Natl. Acad. Sci. USA 109, 273-278.
66. van Schouwenburg, P.A., Rispens, T., Wolbink, G.J., 2013. Immunogenicity of anti- TNF biologic therapies for rheumatoid arthritis. Nat. Rev. Rheumatol. 9, 164-172.
67. Vane, J.R., 1971. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature: New Biol. 231, 232-235.
68. Weinblatt, M.E., Kavanaugh, A., Genovese, M.C., Musser, T.K., Grossbard, E.B., Magilavy, D.B., 2010. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N. Engl. J. Med. 363, 1303-1312.
69. Whang, J.A., Chang, B.Y., 2014. Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Drug Discov. Today 19 (8), 1200-1204. http://dx.doi.org/10.1016/j.drudis.2014.03.028. (Epub 2014 Apr 12).
70. Wu, B., Wilson, A.,Wang, F.F., Wang, S.L., Wallace, D.J., Weisman, M.H., Lu, L.J., 2012. Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china. PLoS One 7, e47373.
71. Xu, D., Kim, Y., Postelnek, J., Vu, M.D., Hu, D.Q., Liao, C., Bradshaw, M., Hsu, J., Zhang, J., Pashine, A., Srinivasan, D.,Woods, J., Levin, A., O'Mahony, A., Owens, T.D., Lou, Y., Hill, R.J., Narula, S., DeMartino, J., Fine, J.S., 2012. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. J. Pharmacol. Exp. Ther. 341, 90-103.
72. Yoshizawa, T., Hammaker, D., Boyle, D.L., Corr, M., Flavell, R., Davis, R., Schett, G., Firestein, G.S., 2009. Role of MAPK kinase 6 in arthritis: distinct mechanism of action in inflammation and cytokine expression. J. Immunol. 183, 1360-1367.